2obq: Difference between revisions
New page: left|200px<br /><applet load="2obq" size="350" color="white" frame="true" align="right" spinBox="true" caption="2obq, resolution 2.5Å" /> '''Discovery of the HCV ... |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The structures of both the native holo-HCV NS3/4A protease domain and the | The structures of both the native holo-HCV NS3/4A protease domain and the protease domain with a serine 139 to alanine (S139A) mutation were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in complex with the protease. The changes in the inhibitor potency were correlated with changes in the buried surface area upon binding the inhibitor to the active site. The largest contribution to the binding energy arises from the hydrophobic interactions of the P1 and P2 groups as they bind to the S1 and S2 pockets [the numbering of the subsites is as defined in Berger, A.; Schechter, I. Philos. Trans. R. Soc. London, Ser. B 1970, 257, 249-264]. This correlation of the changes in potency with increased buried surface area contributed directly to the design of a potent tripeptide inhibitor of the HCV NS3/4A protease that is currently in clinical trials. | ||
==About this Structure== | ==About this Structure== | ||
| Line 15: | Line 15: | ||
[[Category: Arasappan, A.]] | [[Category: Arasappan, A.]] | ||
[[Category: Bennett, F.]] | [[Category: Bennett, F.]] | ||
[[Category: Beyer, B | [[Category: Beyer, B M.]] | ||
[[Category: Bogen, S | [[Category: Bogen, S F.]] | ||
[[Category: Chen, K.]] | [[Category: Chen, K.]] | ||
[[Category: Fischmann, T.]] | [[Category: Fischmann, T.]] | ||
| Line 25: | Line 25: | ||
[[Category: Jao, E.]] | [[Category: Jao, E.]] | ||
[[Category: Liu, Y.]] | [[Category: Liu, Y.]] | ||
[[Category: Love, R | [[Category: Love, R G.]] | ||
[[Category: Madison, V.]] | [[Category: Madison, V.]] | ||
[[Category: Malcolm, B.]] | [[Category: Malcolm, B.]] | ||
[[Category: Myers, Jr., J.]] | [[Category: Myers, Jr., J.]] | ||
[[Category: Njoroge, F | [[Category: Njoroge, F G.]] | ||
[[Category: Pichardo, J.]] | [[Category: Pichardo, J.]] | ||
[[Category: Prongay, A | [[Category: Prongay, A J.]] | ||
[[Category: Prosise, W | [[Category: Prosise, W W.]] | ||
[[Category: Ramanathan, L.]] | [[Category: Ramanathan, L.]] | ||
[[Category: Saksena, A | [[Category: Saksena, A K.]] | ||
[[Category: Senior, M.]] | [[Category: Senior, M.]] | ||
[[Category: Strickland, C.]] | [[Category: Strickland, C.]] | ||
[[Category: Taremi, S | [[Category: Taremi, S S.]] | ||
[[Category: Venkatraman, S.]] | [[Category: Venkatraman, S.]] | ||
[[Category: Weber, P | [[Category: Weber, P C.]] | ||
[[Category: Yang, R.]] | [[Category: Yang, R.]] | ||
[[Category: Yao, N.]] | [[Category: Yao, N.]] | ||
| Line 50: | Line 50: | ||
[[Category: viral protein]] | [[Category: viral protein]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 18:16:40 2008'' | ||
Revision as of 19:16, 21 February 2008
|
Discovery of the HCV NS3/4A Protease Inhibitor SCH503034. Key Steps in Structure-Based Optimization
OverviewOverview
The structures of both the native holo-HCV NS3/4A protease domain and the protease domain with a serine 139 to alanine (S139A) mutation were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in complex with the protease. The changes in the inhibitor potency were correlated with changes in the buried surface area upon binding the inhibitor to the active site. The largest contribution to the binding energy arises from the hydrophobic interactions of the P1 and P2 groups as they bind to the S1 and S2 pockets [the numbering of the subsites is as defined in Berger, A.; Schechter, I. Philos. Trans. R. Soc. London, Ser. B 1970, 257, 249-264]. This correlation of the changes in potency with increased buried surface area contributed directly to the design of a potent tripeptide inhibitor of the HCV NS3/4A protease that is currently in clinical trials.
About this StructureAbout this Structure
2OBQ is a Protein complex structure of sequences from Hepatitis c virus with as ligand. Full crystallographic information is available from OCA.
ReferenceReference
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl] - 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization., Prongay AJ, Guo Z, Yao N, Pichardo J, Fischmann T, Strickland C, Myers J Jr, Weber PC, Beyer BM, Ingram R, Hong Z, Prosise WW, Ramanathan L, Taremi SS, Yarosh-Tomaine T, Zhang R, Senior M, Yang RS, Malcolm B, Arasappan A, Bennett F, Bogen SL, Chen K, Jao E, Liu YT, Lovey RG, Saksena AK, Venkatraman S, Girijavallabhan V, Njoroge FG, Madison V, J Med Chem. 2007 May 17;50(10):2310-8. Epub 2007 Apr 20. PMID:17444623
Page seeded by OCA on Thu Feb 21 18:16:40 2008
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Pages with broken file links
- Hepatitis c virus
- Protein complex
- Arasappan, A.
- Bennett, F.
- Beyer, B M.
- Bogen, S F.
- Chen, K.
- Fischmann, T.
- Girijavallabhan, V.
- Guo, Z.
- Hong, Z.
- Ingram, R.
- Jao, E.
- Liu, Y.
- Love, R G.
- Madison, V.
- Malcolm, B.
- Myers, Jr., J.
- Njoroge, F G.
- Pichardo, J.
- Prongay, A J.
- Prosise, W W.
- Ramanathan, L.
- Saksena, A K.
- Senior, M.
- Strickland, C.
- Taremi, S S.
- Venkatraman, S.
- Weber, P C.
- Yang, R.
- Yao, N.
- Yarosh-Tomaine, T.
- Zhang, R.
- ZN
- Hcv
- Ns3 protease
- Viral protein